



Condensed Interim Financial Statements  
(Expressed in Canadian Dollars)

For the Three Months Ended February 28, 2022 and 2021  
(Unaudited)

#### NOTICE TO READER

The accompanying condensed interim financial statements of NeonMind Biosciences Inc. (“the Company”) have been prepared by management in accordance with International Financial Reporting Standards (“IFRS”). Management acknowledges responsibility for the preparation and presentation of the condensed interim financial statements, including responsibility for significant accounting estimates and the choice of accounting principles and methods that are appropriate to the Company’s circumstances. These condensed interim financial statements have not been reviewed by the Company’s independent auditor.

**NEONMIND BIOSCIENCES INC.**  
Condensed Interim Statements of Financial Position  
(Expressed in Canadian Dollars)

	February 28, 2022 (unaudited)	November 30, 2021
<b>ASSETS</b>		
Current assets		
Cash	\$ 137,172	\$ 773,525
Marketable securities (Note 3)	150,000	193,750
Taxes recoverable (Note 5)	113,486	104,915
Prepaid expenses and deposits (Notes 6 and 8)	204,891	206,741
Total current assets	<u>605,549</u>	<u>1,278,931</u>
Non-current assets		
Restricted cash (Note 4)	57,500	57,500
Equipment	2,415	2,693
Total non-current assets	<u>59,915</u>	<u>60,193</u>
Total assets	<u>\$ 665,464</u>	<u>\$ 1,339,124</u>
<b>LIABILITIES</b>		
Current liabilities		
Accounts payable and accrued liabilities	\$ 608,597	\$ 581,872
Due to related parties (Note 8)	8,411	16,948
Total current liabilities	<u>617,008</u>	<u>598,820</u>
Non-current liabilities		
Convertible debentures (Note 7)	505,032	450,009
Total liabilities	<u>1,122,040</u>	<u>1,048,829</u>
<b>SHAREHOLDERS' EQUITY (DEFICIT)</b>		
Share capital (Note 9)	7,935,582	7,800,880
Reserve for convertible debentures	21,063	21,063
Equity reserves (Notes 10, 11 and 12)	5,557,224	5,557,243
Deficit	<u>(13,970,445)</u>	<u>(13,088,891)</u>
Total shareholders' equity (deficit)	<u>(456,576)</u>	<u>290,295</u>
Total liabilities and shareholders' equity (deficit)	<u>\$ 665,464</u>	<u>\$ 1,339,124</u>

Nature of operations and continuance of business (Note 1)  
Subsequent events (Note 19)

Approved and authorized for issuance on behalf of the Board of Directors on April 25, 2022:

/s/ "Penny White"  
Director

/s/ "Kari Richardson"  
Director

*(The accompanying notes are an integral part of these condensed interim financial statements)*

**NEONMIND BIOSCIENCES INC.**

Condensed Interim Statement of Operations and Comprehensive Loss  
(Expressed in Canadian Dollars)  
(Unaudited)

	Three months ended February 28,	
	2022	2021
<b>EXPENSES</b>		
Consulting fees (Note 8)	\$ 62,499	\$ 39,416
Depreciation	278	15
Investor relations (Note 8)	42,893	95,833
Listing expenses	3,000	6,600
Marketing, publicity, and digital media (Note 8)	164,743	730,454
Office and administrative (Note 8)	70,847	98,657
Pharmaceutical research and development	79,117	267,279
Professional fees (Note 8)	67,110	213,158
Share-based compensation (Notes 11 and 12)	119,981	759,924
Wages (Note 8)	176,368	79,598
Total expenses	<u>786,836</u>	<u>2,290,934</u>
<b>LOSS BEFORE OTHER ITEMS</b>	<u>(786,836)</u>	<u>(2,290,934)</u>
<b>OTHER ITEMS</b>		
Investment loss (Note 13)	(43,750)	(42,643)
Other income & expenses (Note 14)	(50,968)	(8,951)
Total other items	<u>(94,718)</u>	<u>(51,594)</u>
<b>NET LOSS FROM CONTINUING OPERATIONS</b>	<u>(881,554)</u>	<u>(2,342,528)</u>
Net loss from discontinued operations (Note 18)	-	(137,527)
<b>NET AND COMPREHENSIVE LOSS FOR THE PERIOD</b>	<u>\$ (881,554)</u>	<u>\$ (2,480,055)</u>
<b>LOSS PER SHARE, BASIC AND FULLY DILUTED</b>		
- Continuing operations	\$ (0.03)	\$ (0.07)
- Discontinued operations	\$ (0.00)	\$ (0.00)
Weighted average shares outstanding	<u>31,801,101</u>	<u>24,790,862</u>

*(The accompanying notes are an integral part of these condensed interim financial statements)*

## NEONMIND BIOSCIENCES INC.

Condensed Interim Statement of Changes in Shareholders' Equity (Deficit)  
(Expressed in Canadian Dollars)  
(Unaudited)

	Share capital		Reserve for convertible debentures	Equity reserves	Deficit	Total shareholders' equity (deficit)
	Number of shares	Amount				
<b>BALANCE, NOVEMBER 30, 2020</b>	16,607,625	\$ 1,779,158	\$ -	\$ 3,324,813	\$ (5,881,384)	\$ (777,413)
Units issued for cash	11,500,000	4,600,000	-	-	-	4,600,000
Share issuance costs	-	(939,830)	-	365,260	-	(574,570)
Shares issued on exercise of stock options	152,500	98,635	-	(37,635)	-	61,000
Shares issued on exercise of warrants	1,150,750	859,950	-	-	-	859,950
Units issued on exercise of Agent's Options	204,375	146,663	-	(64,913)	-	81,750
Restricted share units vested	405,470	129,751	-	(129,751)	-	-
Fair value of stock options granted	-	-	-	661,435	-	661,435
Fair value of restricted share units granted	-	-	-	98,489	-	98,489
Net loss for the period	-	-	-	-	(2,480,055)	(2,480,055)
<b>BALANCE, FEBRUARY 28, 2021</b>	<b>32,020,720</b>	<b>\$ 6,674,327</b>	<b>\$ -</b>	<b>\$ 4,217,698</b>	<b>\$ (8,361,439)</b>	<b>\$ 2,530,586</b>
<b>BALANCE, NOVEMBER 30, 2021</b>	31,741,634	7,800,880	\$ 21,063	\$ 5,557,243	\$ (13,088,891)	\$ 290,295
Restricted share units issued for services	-	-	-	14,702	-	14,702
Restricted share units vested	402,506	134,702	-	(134,702)	-	-
Fair value of stock options granted	-	-	-	55,618	-	55,618
Fair value of restricted share units granted	-	-	-	64,363	-	64,363
Net loss for the period	-	-	-	-	(881,554)	(881,554)
<b>BALANCE, FEBRUARY 28, 2022</b>	<b>32,144,140</b>	<b>\$ 7,935,582</b>	<b>\$ 21,063</b>	<b>\$ 5,557,224</b>	<b>\$ (13,970,445)</b>	<b>\$ (456,576)</b>

(The accompanying notes are an integral part of these condensed interim financial statements)

**NEONMIND BIOSCIENCES INC.**

Condensed Interim Statement of Cash Flows

(Expressed in Canadian Dollars)

(Unaudited)

	Three months ended February 28,	
	2022	2021
<b>OPERATING ACTIVITIES</b>		
Net loss from continuing operations	\$ (881,554)	\$(2,342,528)
Items not involving cash:		
Accretion	36,273	–
Depreciation	278	15
Interest accrued on convertible debentures	18,750	–
Share of net loss of equity accounted investee	–	42,643
Share-based compensation	119,981	759,924
Unrealized loss on marketable securities	43,750	–
Changes in non-cash operating working capital:		
Amounts receivable	(8,571)	(40,123)
Prepaid expenses and deposits	1,850	(190,816)
Accounts payable and accrued liabilities	41,427	72,731
Due to related parties	(8,537)	5,214
Net cash used in operating activities – continuing operations	(636,353)	(1,692,940)
Net cash used in operating activities – discontinued operations (Note 18)	–	(206,731)
<b>INVESTING ACTIVITIES</b>		
Purchase of equipment	–	(1,285)
Net cash used in investing activities – continuing operations	–	(1,285)
<b>FINANCING ACTIVITIES</b>		
Proceeds from exercise of stock options	–	61,000
Proceeds from issuance of units	–	4,600,000
Share issuance costs	–	(574,570)
Proceeds from exercise of warrants	–	859,950
Proceeds from exercise of Agent's Options	–	81,750
Net cash provided by financing activities – continuing operations	–	5,028,130
<b>CHANGE IN CASH</b>	(636,353)	3,127,174
Cash, beginning of period	773,525	1,170
<b>CASH, END OF PERIOD</b>	<b>\$ 137,172</b>	<b>\$ 3,128,344</b>

Supplemental disclosures (Note 15)

*(The accompanying notes are an integral part of these condensed interim financial statements)*

# NEONMIND BIOSCIENCES INC.

Notes to the Condensed Interim Financial Statements

February 28, 2022 and 2021

(Expressed in Canadian Dollars)

(Unaudited)

## 1. Nature of Operations and Continuance of Business

NeonMind Biosciences Inc. (“NeonMind” or the “Company”) was incorporated under the laws of the province of British Columbia on September 18, 2019. On April 9, 2020, the Company changed its name to NeonMind Biosciences Inc. The Company is engaged in drug development research into potential therapeutic uses of psychedelic compounds. On December 29, 2020, the Company’s common shares were listed on the Canadian Securities Exchange (the “Exchange”) and were immediately halted pending the closing of its initial public offering (“IPO”). On December 30, 2020, the Company completed its IPO and on January 4, 2021 the Company’s common shares resumed trading on the Exchange under the ticker symbol “NEON.”

These condensed interim financial statements have been prepared on the basis that the Company will continue as a going concern, which assumes that the Company will be able to realize its assets and satisfy its liabilities in the normal course of business for the foreseeable future. Management is aware, in making its going concern assessment, of material uncertainties related to events and conditions that may cast significant doubt upon the Company’s ability to continue as a going concern.

The Company has incurred a net loss from continuing operations of \$881,554 and used \$636,353 of cash for operating activities from continuing operations during the period ended February 28, 2022. As of February 28, 2022, the Company had an accumulated deficit of \$13,970,445. The continued operations of the Company are dependent on future profitable operations, management’s ability to manage costs, and the future availability of equity or debt financing. Whether and when the Company can generate sufficient operating cash flows to pay for its expenditures and settle its obligations as they fall due is uncertain. These condensed interim financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and statement of financial position classifications that would be necessary were the going concern assumption be inappropriate. The impact of these adjustments could be material.

The recent outbreak of the novel coronavirus COVID-19, which was declared a pandemic by the World Health Organization on March 11, 2020, has led to adverse impacts on the Canadian and global economies, disruptions of financial markets, and created uncertainty regarding potential impacts to the Company’s supply chain and operations. The COVID-19 pandemic has impacted and could further impact the Company’s operations and the operations of the Company’s suppliers and vendors as a result of quarantines, facility closures, and travel and logistics restrictions. The extent to which the COVID-19 pandemic impacts the Company’s business, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to the duration, spread, severity, and impact of the COVID-19 pandemic, the effects of the COVID-19 pandemic on the Company’s suppliers and vendors and the remedial actions and stimulus measures adopted by local and federal governments, and to what extent normal economic and operating conditions can resume. The management team is closely following the progression of COVID-19 and its potential impact on the Company and is working on alternative measures and resources to minimize such impact. Even after the COVID-19 pandemic has subsided, the Company may experience adverse impacts to its business as a result of any economic recession or depression that has occurred or may occur in the future. Therefore, the Company cannot reasonably estimate the impact at this time our business, liquidity, capital resources and financial results.

## NEONMIND BIOSCIENCES INC.

Notes to the Condensed Interim Financial Statements

February 28, 2022 and 2021

(Expressed in Canadian Dollars)

(Unaudited)

### 2. Significant Accounting Policies

#### Statement of Compliance

These condensed interim financial statements of the Company have been prepared in accordance with International Accounting Standards 34, *Interim Financial Reporting*, and based on the principles of International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) and the interpretations of the International Financial Reporting Interpretations Committee. These condensed interim financial statements should be read in conjunction with the Company’s annual financial statements for the year ended November 30, 2021, which include the Company’s significant accounting policies, and have been prepared in accordance with the same methods of application.

#### Basis of Presentation

These condensed interim financial statements have been prepared on a historical cost basis. In addition, these condensed interim financial statements have been prepared using the accrual basis of accounting, except for the cash flow information. The presentation and functional currency of the Company is the Canadian dollar.

In the opinion of the Company’s management, all adjustments considered necessary for a fair presentation have been included.

#### Significant Accounting Estimates and Judgments

The preparation of condensed interim financial statements in accordance with IFRS requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets, liabilities, income, and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

Significant areas requiring the use of estimates include the useful life and carrying value of property and equipment, fair value of share-based compensation, and measurement of unrecognized deferred income tax assets.

Judgments made by management in the application of IFRS that have a significant effect on the condensed interim financial statements include the factors that are used in determining whether the Company has significant influence over another entity, and the application of the going concern assumption which requires management to consider all available information about the future, which is at least but not limited to 12 months from the end of the reporting period.

The Company had previously determined that it had significant influence in Komo Plant Based Comfort Foods Inc. (“Komo Foods”) despite holding less than 20% of the voting rights in Komo Foods due to the company sharing a common CFO, and the fact that the Company and Komo Foods entered into a license agreement that was a key component of Komo Food’s business in prior periods. As a result, Komo Foods was considered an associate of the Company, and the investment in Komo Foods was accounted for using the equity method. The equity method involves recording the initial investment at cost and subsequently adjusting the carrying value of the investment for the Company’s proportionate share of the profit or loss, other comprehensive income or loss and any other changes in the associate’s net assets, such as further investments or dividends. During the year ended November 30, 2021, Komo Foods entered into a merger agreement and management determined that significant influence in Komo Foods no longer existed (Note 13) and the Company reclassified its investment to fair value through profit and loss under IFRS 9, *Financial Instruments*.



## NEONMIND BIOSCIENCES INC.

Notes to the Condensed Interim Financial Statements

February 28, 2022 and 2021

(Expressed in Canadian Dollars)

(Unaudited)

### 2. Significant Accounting Policies (continued)

#### Reclassification of Prior Year Presentation

Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no material effect on the condensed interim statement of financial position or the reported results of operations. An adjustment has been made on the condensed interim statement of operations to separate out foreign exchange gain and interest expense from office and administrative into separate line items under other expenses.

#### Future Accounting Pronouncements

Certain pronouncements have been issued by the IASB, or the IFRS Interpretations Committee that are not mandatory for the current period and have not been early adopted. Management has assessed that there are no future accounting pronouncements that are expected to have a material impact on the Company in the current or future reporting periods.

### 3. Marketable Securities

Below is a summary of the Company's marketable securities as of February 28, 2022:

	November 30, 2021 fair value	Additions	Proceeds from sale	Realized gain (loss)	Unrealized loss	February 28, 2022 fair value
Komo YUM Shares	\$ 193,750	\$ -	\$ -	\$ -	\$ (43,750)	\$ 150,000

As at February 28, 2022, the Company held 1,250,000 shares (November 30, 2021 – 1,250,000) of Komo Plant Based Foods Inc. ("Komo YUM").

### 4. Restricted Cash

During the year ended November 30, 2021, the Company invested in a variable rate GIC in the principal amount of \$57,500 as security for the credit card with the Company's banking institution. All renewals and replacements and all interest shall be held by the bank as continuing security.

### 5. Taxes recoverable

	February 28, 2022	November 30, 2021
GST input tax credits	113,486	104,915

### 6. Prepaid Expenses and Deposits

	February 28, 2022	November 30, 2021
Deposits	\$ 64,315	\$ 74,786
Prepaid services	140,576	131,955
Total prepaid expenses and deposits	\$ 204,891	\$ 206,741

Prepaid services consisted of advance payments for future capital conferences that were put on hold due to the impact of the COVID-19 pandemic, media consulting services, and insurance policies.

## NEONMIND BIOSCIENCES INC.

Notes to the Condensed Interim Financial Statements  
February 28, 2022 and 2021  
(Expressed in Canadian Dollars)  
(Unaudited)

### 7. Convertible Debentures

Proceeds from issue of convertible debentures	\$ 750,000
Transaction costs – cash	(157,570)
Net proceeds	<u>592,430</u>
Transaction costs – non-cash	(61,993)
Amount classified as equity	(21,063)
Fair value of warrants attached to units	(59,976)
Accrued interest	208
Accretion	403
Carrying amount of liability at November 30, 2021	\$ 450,009
Accrued interest	18,750
Accretion	36,273
Carrying amount of liability at February 28, 2022	<u>\$ 505,032</u>

On November 29, 2021, the Company issued 750 convertible debenture units at a price of \$1,000 per unit for gross proceeds of \$750,000. Each unit consisted of a repayable note with a face value of \$1,000 (the “Debentures”) and 2,000 warrants to purchase common shares of the Company. The Debentures bear interest at a rate of 10% per annum on an accrual basis from issuance, calculated and payable semi-annually in arrears on May 31 and November 30 of each year.

The Debentures have a redemption date that is 24 months from the date of issuance and are convertible in full or in part, at the holders’ option, into common shares of the Company at a price of \$0.48 per common share, at any time prior to their redemption. Each warrant entitles the holder thereof to acquire one common share of the Company at a price of \$0.56 per share for a period of 36 months from the date of issue.

In connection with the issuance of the Debentures, the Company paid broker fees of \$82,570, commission fees of \$75,000, and granted 156,250 agent’s options (the “Agent’s Options”) with a fair value of \$61,993 entitling the holder to purchase a unit of the Company (the “Agent’s Option Unit”) at \$0.48 per Agent’s Option until November 29, 2023. Each Agent’s Option Unit consists of one common share of the Company (each, an “Agent’s Option Share”) and one share purchase warrant (each, an “Agent’s Option Warrant”). Each Agent’s Option Warrant further entitles the holder to purchase one additional common share of the Company at a price of \$0.56 for a period of 36 months from the Agent’s Options issue date of November 29, 2021. The estimated fair value associated with the Agent’s Options granted was determined using the Black-Scholes Pricing model with the following assumptions: stock price at grant date of \$0.564; annualized volatility of 132%; expected life of 2 years; dividend yield of 0%; expected forfeiture rate of 0%; and risk-free rate of 1.08%.

During the period ended February 28, 2022, the Company accrued interest of \$18,750 (2021 - \$nil) relating to the Debentures.

### 8. Related Party Transactions

During the three months ended February 28, 2022 and 2021 compensation of key management personnel and related parties were as follows:

	Three months ended February 28,	
	2022	2021
Consulting fees	\$ 59,124	\$ 39,416
Share-based compensation	170,697	616,491
Wages	167,500	74,017
	<u>\$ 397,321</u>	<u>\$ 729,924</u>

## NEONMIND BIOSCIENCES INC.

Notes to the Condensed Interim Financial Statements

February 28, 2022 and 2021

(Expressed in Canadian Dollars)

(Unaudited)

### 8. Related Party Transactions (continued)

As at February 28, 2022, a related company, Better Plant Sciences Inc. ("Better Plant"), held a \$10,000 deposit from the Company (November 30, 2021 - \$10,000) which is included in prepaid expenses and deposits. As at February 28, 2022, the Company owed \$8,411 (November 30, 2021 - \$16,948) to Better Plant. The balance is unsecured, non-interest bearing, and due on demand.

During the period ended February 28, 2022, the Company incurred marketing expenses of \$1,693 (February 28, 2021 - \$25,494), investor relations expenses of \$13,594 (February 28, 2021 - \$31,833), professional fees of \$21,139 (February 28, 2021 - \$58,547), office and administrative expenses of \$9,220 (February 28, 2021 - \$21,618), and consumer product research and development expenses of \$nil (February 28, 2021 - \$24,877) from Better Plant. Better Plant provided such services to the Company pursuant to an operating agreement dated August 30, 2020.

### 9. Share Capital

Authorized: unlimited number of common shares without par value.

On April 18, 2022, the Company effected a 1-for-4 share consolidation. All share and per share amounts in these condensed interim financial statements have been retroactively adjusted for the share consolidation.

- (a) During the three months ended February 28, 2022, the Company issued 402,506 common shares pursuant to the conversion of fully vested restricted share units. The fair value of the restricted share units of \$134,702 was transferred from equity reserves to share capital upon conversion.

During the three months ended February 28, 2021, the Company completed the following transactions:

- (b) On December 30, 2020, the Company completed its IPO of 11,500,000 units at \$0.40 per unit for proceeds of \$4,600,000. Each unit consisted of one common share and one share purchase warrant exercisable at \$0.80 per share until December 30, 2021. In connection with the IPO, the Company paid broker fees of \$45,000, commission fees of \$460,000, due diligence fees of \$69,570, and issued 1,150,000 agents' options (the "Agents' Options") with a fair value of \$365,260, entitling the holder to purchase a unit of the Company (the "Agent's Option Unit") at \$0.40 per Agent's Option Unit until December 30, 2022. Each Agent's Option Unit consists of one common share of the Company (each, an "Agent's Option Share") and one share purchase warrant (each, an "Agent's Option Warrant"). Each Agent's Option Warrant further entitles the holder to purchase one additional common share of the Company for a period of 24 months from the IPO closing date on December 30, 2020. The estimated fair value associated with the Agent's Options granted was determined using the Black-Scholes Pricing model with the following assumptions: stock price at grant date of \$0.40; an annualized volatility of 179%; an expected life of 2 years; a dividend yield of 0%; a forfeiture rate of 0% and a risk free rate of 0.20%.
- (c) The Company issued 152,500 common shares for proceeds of \$61,000 pursuant to the exercise of stock options. The fair value of the stock options of \$37,635 was transferred from equity reserves to share capital upon exercise.
- (d) The Company issued 1,150,750 common shares for proceeds of \$859,950 pursuant to the exercise of warrants.
- (e) The Company issued 405,470 common shares pursuant to the conversion of fully vested restricted share units. The fair value of the restricted share units of \$129,751 was transferred from equity reserves to share capital upon conversion.

## NEONMIND BIOSCIENCES INC.

Notes to the Condensed Interim Financial Statements

February 28, 2022 and 2021

(Expressed in Canadian Dollars)

(Unaudited)

### 9. Share Capital (continued)

- (f) The Company issued 204,375 Agent's Option Shares and 204,375 Agent's Option Warrants pursuant to the exercise of Agent's Options for proceeds of \$81,750. Each Agent's Option Warrant entitles the holder to purchase one additional common share of the Company at \$0.80 per common share for a period of 24 months from the IPO closing date on December 30, 2020. The fair value of the Agent's Option Warrants of \$64,913 was transferred from equity reserves to share capital upon exercise.

### 10. Share Purchase Warrants

On April 18, 2022, the Company effected a 1-for-4 share consolidation. Figures in the tables below have been retroactively adjusted for the share consolidation.

The following table summarizes the continuity of the Company's share purchase warrants:

	Number of warrants	Weighted average exercise price
Balance, November 30, 2020	22,038,237	\$ 1.20
Issued	14,865,950	0.74
Exercised	(2,441,937)	0.60
Expired	(537,500)	2.00
Balance, November 30, 2021	33,924,750	\$ 1.00
Expired	(6,834,125)	2.00
Balance, February 28, 2022	27,090,625	\$ 0.69
Exercisable, February 28, 2022	18,840,625	\$ 0.64

As at February 28, 2022, the following share purchase warrants were outstanding:

Number of warrants outstanding	Exercise price	Expiry date
96,875	\$ 0.40	March 23, 2022
25,000	\$ 0.40	March 25, 2022
62,500	\$ 0.40	April 27, 2022
13,750,000	\$ 0.20	May 6, 2022
10,350,000	\$ 0.14	June 30, 2022 <sup>1</sup>
633,125	\$ 0.10	December 30, 2022
516,875	\$ 0.20	December 30, 2022
156,250	\$ 0.14	November 29, 2023
1,500,000	\$ 0.14	November 29, 2024
<u>27,090,625</u>		

<sup>1</sup> On December 15, 2021, the Company amended the terms of 10,350,000 warrants which were previously issued in connection with the initial public offering of the Company that closed on December 30, 2020. The warrants originally entitled the holders to purchase one common share in the capital of the Company at a price of \$0.80 for a period of 12 months. The expiry date of the warrants has been extended to June 30, 2022, and the exercise price has been reduced to \$0.56.

## NEONMIND BIOSCIENCES INC.

Notes to the Condensed Interim Financial Statements

February 28, 2022 and 2021

(Expressed in Canadian Dollars)

(Unaudited)

### 11. Stock Options

On January 13, 2020, the Company adopted an incentive stock option plan, which was replaced by an amended and restated incentive stock option plan on September 9, 2020. Pursuant to the Company's stock option plan, directors may, from time to time, authorize the issuance of options to directors, officers, employees, and consultants of the Company. The terms of the granted stock options as well as the vesting conditions are at the sole discretion of the directors.

On April 18, 2022, the Company effected a 1-for-4 share consolidation. Figures in the tables below have been retroactively adjusted for the share consolidation.

The following table summarizes the continuity of the Company's stock options:

	Number of options	Weighted average exercise price
Outstanding, November 30, 2020	1,572,500	\$ 0.40
Granted	3,738,750	0.92
Exercised	(277,500)	0.40
Expired/Cancelled	(170,625)	0.40
Outstanding, November 30, 2021	4,863,125	\$ 0.80
Granted	175,000	0.40
Expired/Cancelled	(354,375)	0.84
Outstanding, February 28, 2022	4,683,750	\$ 0.79
Exercisable, February 28, 2022	2,969,375	\$ 0.80

Additional information regarding stock options outstanding and exercisable as at February 28, 2022:

Range of exercise prices	Stock options outstanding	Stock options exercisable	Weighted average remaining contracted life (years)
\$0.40 - \$0.59	1,332,500	816,875	0.91
\$0.60 - \$0.99	981,250	441,250	0.86
\$1.00 - \$1.28	2,370,000	1,711,250	1.83
	4,683,750	2,969,375	3.60

Share-based compensation expense related to stock options was determined using the Black-Scholes option pricing model. During the three months ended February 28, 2022, the Company recognized share-based compensation expense relating to stock options of \$55,618 (2021 - \$661,435) in equity reserves, of which \$131,411 (2021 - \$518,002) pertains to directors and officers of the Company. The expense pertaining to directors and officers of the Company is larger than the overall expense as a result of accounting for stock options cancelled during the period. The weighted average fair value of options granted during the three months ended February 28, 2022, was \$0.20 (2021 - \$0.92) per share. There were no stock options exercised during the three months ended February 28, 2022. The weighted average share price for stock options exercised during the three months ended February 28, 2021 was \$0.92. Weighted average assumptions used in calculating the fair value of share-based compensation expense, including no expected dividends or forfeitures, are as follows:

	2022	2021
Risk-free interest rate	1.64%	0.47%
Dividend yield	0%	0%
Expected volatility	124%	147%
Expected life (years)	4.52	4.97

As at February 28, 2022 there was \$381,507 (November 30, 2021 - \$589,721) of unrecognized share-based compensation related to unvested stock options.

## NEONMIND BIOSCIENCES INC.

Notes to the Condensed Interim Financial Statements

February 28, 2022 and 2021

(Expressed in Canadian Dollars)

(Unaudited)

### 12. Restricted Share Units

On April 16, 2020, the Company adopted a restricted share unit plan, which was replaced by an amended and restated restricted share unit plan on April 27, 2020, September 9, 2020 and November 3, 2020. Pursuant to the Company's restricted share unit plan, directors may, from time to time, authorize the issuance of restricted share units to directors, officers, employees, and consultants of the Company. The terms of the granted restricted share units as well as the vesting conditions are at the sole discretion of the directors.

On April 18, 2022, the Company effected a 1-for-4 share consolidation. Figures in the tables below have been retroactively adjusted for the share consolidation.

	Number of Restricted share units
Balance, November 30, 2020	2,299,220
Granted	404,725
Cancelled	(164,375)
Vested	(914,570)
Balance, November 30, 2021	1,625,000
Granted	102,506
Vested	(402,506)
Balance, February 28, 2022	1,325,000

Share-based compensation expense relating to restricted share units was determined using the fair value of common shares of the Company on the date of grant. For restricted share units issued prior to the IPO on December 30, 2020, the fair value was determined based on previous private placements with third parties. For restricted share units issued subsequent to the IPO, the fair value was determined using the market price of the Company's common shares. During the three months ended February 28, 2022, the Company recognized share-based compensation expense relating to restricted share units of \$64,363 (2021 - \$98,489) in equity reserves, \$39,286 (2021 - \$98,489) of which pertains to directors and officers of the Company. During the three months ended February 28, 2022, the Company granted restricted share units with a total fair value of \$14,702 (2021 - \$nil) in exchange for consulting services. The weighted average fair value of restricted share units granted during the three months ended February 28, 2022, was \$0.28 (2021 - \$1.04) per share.

As at February 28, 2022 there was \$165,930 (November 30, 2021 - \$183,567) of unrecognized share-based compensation related to unvested restricted share units.

### 13. Investment Loss

	Three months ended February 28,	
	2022	2021
Share of net loss of equity accounted investee	\$ -	\$ (42,643)
Unrealized loss on marketable securities (Note 3)	(43,750)	-
	\$ (43,750)	\$ (42,643)

On February 21, 2020, the Company entered into a license agreement with Komo Foods, a plant based food company, whereby the Company granted Komo Foods a non-exclusive license to the Company's mushroom extraction technology for use in the United States. Pursuant to the license agreement, the Company received 1,250,000 common shares of Komo Foods, with a fair value of \$415,000, representing a 4.05% ownership interest in Komo Foods at the time of the transaction.

## NEONMIND BIOSCIENCES INC.

Notes to the Condensed Interim Financial Statements

February 28, 2022 and 2021

(Expressed in Canadian Dollars)

(Unaudited)

### 13. Investment Loss (continued)

The Company had determined that it had significant influence in Komo Foods as it shared a common CFO, and there had been significant transactions including the licensing agreement entered into with Komo Foods. As a result of having significant influence in Komo Foods, the Company's investment in Komo Foods was accounted for as an investment in an associate using the equity method. The equity method involves recording the initial investment at cost and subsequently adjusting the carrying value of the investment for the Company's proportionate share of the profit or loss, other comprehensive income or loss and any other changes in the associate's net assets, such as further investments or dividends.

During the period ended February 28, 2021, the Company recorded its proportionate loss from Komo Foods of \$42,643. The following table outlines the changes in investment in associate that was accounted for using the equity method for the three months ended February 28, 2021. As the Company does not have the same reporting date as its associate, the Company was provided with unaudited financial statements for the three months ended February 28, 2021 to calculate the portion of net loss attributable to the Company.

	Three months ended February 28, 2021	
Komo Foods net income (loss)	<u>\$ (1,520,959)</u>	
% ownership	2.67%	
Portion of net income (loss) from investment in associate	<u>\$ (42,643)</u>	

On May 31, 2021, Komo Foods entered into a merger agreement with Komo YUM. Subsequent to the merger, the Company's shares of Komo Foods were exchanged 1-to-1 for Komo YUM shares and it was determined that the Company no longer had significant influence over Komo YUM. As a result, the Company began accounting for the investment in Komo Foods as marketable securities at fair value through profit or loss. For the three month ended February 28, 2022, the Company recorded an unrealized loss on marketable securities of \$43,750.

### 14. Other Income & Expenses

	Three months ended February 28,	
	2022	2021
Accretion expense (Note 7)	\$ (36,273)	\$ -
Foreign exchange gain	4,055	83
Interest expense (Note 7)	(18,750)	(9,034)
	<u>\$ (50,968)</u>	<u>\$ (8,951)</u>

### 15. Supplemental Disclosures

	Three months ended February 28,	
	2022	2021
Non-cash investing and financing activities:		
Restricted share units issued to settle accounts payable	\$ 14,702	\$ -
Transfer of fair value of options to share capital upon exercise	-	37,635
Transfer of fair value of warrants to share capital upon exercise	-	64,913
Fair value of Agent's Options issued as finder's fees	-	365,260
Fair value of restricted share units converted	<u>\$ 134,702</u>	<u>\$ 129,751</u>

## NEONMIND BIOSCIENCES INC.

Notes to the Condensed Interim Financial Statements

February 28, 2022 and 2021

(Expressed in Canadian Dollars)

(Unaudited)

### 16. Capital Management

The Company manages its capital structure and makes adjustments, based on the funds available to the Company, to support the general operations of the Company and facilitate the liquidity needs of its operations. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. The Company defines capital to include its working capital position and share capital.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. The Company is not subject to externally imposed capital requirements.

### 17. Financial Instruments and Risk Management

#### Fair Values

Assets and liabilities measured at fair value on a recurring basis were presented on the statement of financial position as at February 28, 2022, as follows:

	Fair Value Measurements Using			Balance, February 28, 2022
	Quoted prices in active markets for identical instruments (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)	
Marketable securities	\$ 150,000	\$ –	\$ –	\$ 150,000
Restricted cash	57,500	–	–	57,500
Convertible debentures	–	505,032	–	505,032
	<u>\$ 207,500</u>	<u>\$ 505,032</u>	<u>\$ –</u>	<u>\$ 712,532</u>

The fair values of other financial instruments, including cash, accounts payable and accrued liabilities, and amounts due to related parties approximate their carrying values due to the relatively short-term maturity of these instruments.

#### Credit Risk

Credit risk is the risk of loss that may arise on outstanding financial instruments should a counter-party default on its obligation. The Company's credit risk is primarily attributable to cash. The Company minimizes its credit risk associated with its cash balance by dealing with major financial institutions in Canada and has no other significant concentration of credit risk arising from operations. The carrying amount of financial assets represents the maximum credit exposure.

#### Foreign Exchange Rate and Interest Rate Risk

The Company is not exposed to any significant foreign exchange rate or interest rate risk.

#### Liquidity Risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting financial obligations due to shortage of funds. The Company manages liquidity risk by maintaining sufficient cash balances and adjusting its operating budget and expenditure. Liquidity requirements are managed based on expected cash flows to ensure that there are sufficient funds to meet short-term and specific obligations.



## NEONMIND BIOSCIENCES INC.

Notes to the Condensed Interim Financial Statements

February 28, 2022 and 2021

(Expressed in Canadian Dollars)

(Unaudited)

### 17. Financial Instruments and Risk Management (continued)

#### Price Risk

The Company is exposed to price risk with respect to its marketable securities, which consists of common shares held in publicly-traded companies and is dependent upon the market price or the fair value of the common shares for those companies. The market price or the fair value of the common shares of those companies can fluctuate significantly, and there is no assurance that the future market price or the fair value of those companies will not decrease significantly.

### 18. Discontinued Operations

The Company entered into an Asset Purchase Agreement dated September 10, 2021 with Better Plant in which the Company agreed to sell certain assets in consideration for \$645,000. The following assets were transferred by the Company to Better Plant: four mushroom coffee products being sold in Canada at the time of sale and four mushroom coffee dietary products, including existing inventory, raw materials and packaging for all eight products, social media accounts related to the products, a domain neonmind.com and the neonmind.com Shopify-enabled website in Canada and the US, as well as associated marketing materials and a license to use the brand NeonMind in association with the products.

As a result of the sale of the assets pertaining to the functional mushroom coffee consumer products (the "Consumer Products Division"), as well as management's decision to no longer pursue this retail division, the Consumer Products Division meets the criteria to be classified as discontinued operations as of September 10, 2021, and therefore the results of operations of the Consumer Products Division for all periods have been classified as discontinued operations on the condensed interim statements of operations.

Net Loss from Discontinued Operations

	Three months ended February 28, 2021
Consumer Products Division	
REVENUE	
Product sales	\$ 8,115
Cost of sales	<u>2,031</u>
Gross profit	<u>6,084</u>
EXPENSES	
Amortization	1,013
Information systems	1,480
Marketing, publicity, and digital media	72,987
Office and administrative	5,281
Research and development – consumer products	48,526
Professional fees	<u>14,324</u>
Total expenses	<u>143,611</u>
NET LOSS	<u>\$ (137,527)</u>

## NEONMIND BIOSCIENCES INC.

Notes to the Condensed Interim Financial Statements

February 28, 2022 and 2021

(Expressed in Canadian Dollars)

(Unaudited)

### 18. Discontinued Operations (continued)

Cash Flows from Discontinued Operations	Three months ended February 28, 2021
Consumer Products Division	
<u>OPERATING ACTIVITIES</u>	
Net loss	\$ (137,527)
Items not involving cash	
Amortization	1,012
Changes in non-cash operating working capital	
Accounts receivable	(740)
Inventory	(7,036)
Accounts payable and accrued liabilities	(62,220)
Deferred revenue	(220)
Net cash used in operating activities	<u>\$ (206,731)</u>

### 19. Subsequent Events

On April 8, 2022, the Company closed its non-brokered private placement (the “Offering”) of units of convertible unsecured debentures (the “Debentures”) and warrants (the “Warrants”) of the Company. Pursuant to the Offering, the Company issued 394 units at a price of \$1,000 per unit for gross proceeds of \$394,000. Each unit consists of one Debenture in the principal amount of \$1,000 and 2,375 Warrants to purchase common shares of the Company. Of the units issued, 109 units were issued for debt settlement.

The Debentures bear interest at a rate of 10% per annum on an accrual basis from issuance, calculated and payable semi-annually in arrears on May 31 and November 30 of each year with a redemption date that is 24 months from issuance. The Debentures are convertible in full or in part, at the holders’ option, into common shares in the capital of the Company at a price of \$0.30 per common share, at any time prior to their redemption. Each Warrant will entitle the holder thereof to acquire one common share of the Company at a price of \$0.32 per share for a period of 36 months from the date of issue.

In connection with the closing of the Offering, the Company paid a cash commission of \$14,000 and granted 33,250 Agent’s Options with each such Agent’s Option entitling the holder to purchase a unit of the Company (the “Agent’s Option Unit”) at \$0.30 per Agent’s Option Unit until April 8, 2024. Each Agent’s Option Unit consists of one common share of the Company (each, an “Agent’s Option Share”) and one share purchase warrant (each, an “Agent’s Option Warrant”). Each Agent’s Option Warrant further entitles the holder to purchase one additional common share of the company at a price of \$0.32 for a period of 36 months from the date of issue of the Agent’s Options on April 8, 2022.